Hisamitsu Pharmaceutical Co. Inc. reported consolidated and non-consolidated earnings results for the third quarter and nine months ended November 30, 2016. For the quarter, on consolidated basis the company has posted sales of ¥35,282 million against ¥39,854 million a year ago. Operating profits were ¥9,120 million against ¥8,815 million a year ago. Net profits were ¥9,054 million against ¥5,941 million a year ago. Pre-tax profit was ¥13,219 million against ¥8,840 million a year ago.

For the nine months, on consolidated basis the company has posted sales of ¥109,729 million against ¥122,283 million a year ago. Operating profits were ¥21,995 million against ¥23,324 million a year ago. Net profits were ¥18,340 million against ¥15,318 million a year ago. Pre-tax profit was ¥27,031 million against ¥23,439 million a year ago.

For the quarter, on non-consolidated basis the company has posted sales of ¥27,111 million against ¥29,430 million a year ago. Operating profits were ¥7,602 million against ¥7,453 million a year ago. Net profits were ¥6,010 million against ¥5,158 million a year ago. Pre-tax profit was ¥8,530 million against ¥7,709 million a year ago.

For the nine months, on non-consolidated basis the company has posted sales of ¥83,187 million against ¥90,287 million a year ago. Operating profits were ¥17,887 million against ¥21,187 million a year ago. Net profits were ¥14,145 million against ¥14,605 million a year ago. Pre-tax profit was ¥20,070 million against ¥21,775 million a year ago.

The company provided consolidated and non-consolidated earnings guidance for the fiscal year of 2017. For the year, on consolidated basis the company has expects sales of ¥155,000 million. Operating profits were ¥28,000 million. Net profits were ¥19,400 million. Pre-tax profit was ¥20,070 million.

For the year, on non-consolidated basis the company has expects sales of ¥119,500 million. Operating profits were ¥24,500 million. Net profits were ¥18,000 million. Pre-tax profit was ¥26,800 million.